The Washington Biotechnology & Biomedical Association (WBBA) announced today that Chris Porter has joined the organization to dedicate a portion of his time as its Commercialization Consultant. WBBA’s mission is to translate “Innovation to Realization, from breakthrough discoveries to better health solutions.” As part of this mission, the WBBA’s commercialization team assists life sciences researchers and entrepreneurs in advancing their ideas and companies through a broad range of activities, including: pro-bono start-up consultation and mentoring, capital formation and industry introductions. In 2010 alone, the WBBA’s commercialization team mentored more than 50 newly formed life science companies in Washington, with nearly one-third of them becoming successful in raising capital, attracting management and developing strategic partnerships.
Since 2009, the WBBA has been facilitating the development of translational research and commercialization of life science technologies. Some of the organization’s initiatives, in addition to providing pro-bono consultation include: the formation of WINGS, Washington’s Med Tech Angel Network (www.medtechwings.com); VIP Forums, where more than a dozen venture capital and strategic organizations from outside the region have met with dozens of Washington companies; and the establishment of www.lifesciencestartup.com, a wiki web site for Washington-based, start-up life science organizations.
"We are thrilled to have Chris join us. Our commercialization efforts are a key cornerstone of the WBBA, and having someone with Chris’s experience, talent and connections will undoubtedly help us continue our momentum of ‘Innovation to Realization,’” said Chris E. Rivera, President of WBBA. “As a long-time industry leader, Chris brings decades of relevant knowledge to the position, including strategic partnering, financial acumen, and specific expertise in starting and building successful life science companies.”
“This is a very exciting opportunity for me to help our growing life science community,” stated Porter. “The WBBA has done a tremendous job helping dozens of companies hone their business strategy, access capital and establish early momentum in their quest to bring their innovations to market, and I look forward to working with the WBBA to fulfill its mission.”
Chris has had a successful 34-year career in the medical-device and biotechnology industry. He has been influential in introducing over 30 medical products and is the holder of 41 US patents. Chris has served in a variety of positions (CEO, General Manager, top technical and top manufacturing positions) in both major corporations (3M, Johnson and Johnson, and Pfizer) and early stage medical companies. These experiences have given him an excellent overview on how to start, value, finance, organize and lead a successful medical products business. He has been an important part of creating in excess of $2.0-billion dollars in shareholder value. Chris is and has been a CEO and/or board member of numerous public and private companies. He has founded, invented products for, and/or contributed heavily to the success of numerous medical-device companies and started three divisions within major corporations. He is an experienced and successful fundraiser including: venture financing, corporate partnerships, out-licensing, acquisitions (both buyer and seller) and IPOs. He has conducted “due diligence” for several venture firms and has made a number of investments in early stage companies.
At present, Chris runs Medical Genesis, a consulting firm and medical device incubator. He is also devoting most of his efforts towards assisting early-stage companies by mentoring and participating in entrepreneurial education and technology transfer at Seattle U and UW. He serves on several boards and screening committees and is also very active in several non-profits. Chris has a Ph.D. in Chemical and Material Engineering. He has two grown children and lives with his wife Kathryn in Woodinville, WA.
Rivera adds, "I'd also like to sincerely thank Stewart Parker for her efforts over the past year as our Commercialization Consultant. Stewart’s track record helping our start-up community has been unprecedented! We are also thrilled to see Stewart take over as CEO of Infectious Disease Research Institute (IDRI), and hope to see many innovations from IDRI come through our commercialization team in the future. We wish Stewart continued success.“
To take advantage of WBBA’s guidance, strategy, and feedback, WBBA members should e-mail email@example.com to set up a consultation. To become a member, please see details in our Member Center at http://www.washbio.org.Business Wire
Last updated on: 01/03/2011